TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Stagezero Life Sciences (OTCMKTS:SZLSF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Institutional & Insider Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 2.5% of Stagezero Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares TriSalus Life Sciences and Stagezero Life Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $29.43 million | 11.66 | -$30.05 million | ($2.02) | -3.40 |
| Stagezero Life Sciences | $3.80 million | 0.02 | -$11.41 million | ($0.01) | -0.05 |
Stagezero Life Sciences has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
TriSalus Life Sciences has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Stagezero Life Sciences has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for TriSalus Life Sciences and Stagezero Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
| Stagezero Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
TriSalus Life Sciences currently has a consensus target price of $11.00, indicating a potential upside of 60.12%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Stagezero Life Sciences.
Profitability
This table compares TriSalus Life Sciences and Stagezero Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -98.45% | N/A | -111.88% |
| Stagezero Life Sciences | N/A | N/A | N/A |
Summary
TriSalus Life Sciences beats Stagezero Life Sciences on 8 of the 13 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Stagezero Life Sciences
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
